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Abstract
Background
Few studies have assessed the burden of Chagas disease in non-endemic countries and
most of them are based on prevalence estimates from Latin American (LA) countries that
likely differ from the prevalence in migrants living in Europe. The aim of this study was to
systematically review the existing data informing current understanding of the prevalence of
Chagas disease in LA migrants living in European countries.
Methods
We conducted a systematic review and meta-analysis of studies reporting prevalence of
Chagas disease in European countries belonging to the European Union (EU) before 2004
in accordance with the MOOSE guidelines and based on the database sources MEDLINE
and Global Health. No restrictions were placed on study date, study design or language of
publication. The pooled prevalence was estimated using random effect models based on
DerSimonian & Laird method.
Results
We identified 18 studies conducted in five European countries. The random effect pooled
prevalence was 4.2% (95%CI:2.2-6.7%); and the heterogeneity of Chagas disease preva-
lence among studies was high (I2 = 97%,p<0.001). Migrants from Bolivia had the highest
prevalence of Chagas disease (18.1%, 95%CI:13.9–22.7%).
Conclusions
Prevalence of Chagas in LA migrants living in Europe is high, particularly in migrants from
Bolivia and Paraguay. Data are highly heterogeneous dependent upon country of origin and
within studies of migrants from the same country of origin. Country-specific prevalence dif-
fers from the estimates available from LA countries. Our meta-analysis provides prevalence
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Author Summary
Chagas disease is emerging in European countries due to the migration flows from Latin-
American endemic countries to Europe, particularly to southern countries. Some studies
have evaluated the prevalence of this disease in several European countries although these
estimates are based on national population prevalence rates from countries of origin and
the estimated size of the corresponding migrant population. The objective of this study is
to review the studies about the prevalence of Chagas disease in Latin American migrants
living in European countries. Our meta-analysis provides prevalence estimates of Chagas
disease that should be used to estimate the burden of disease in European countries. This
accurate data about country specific prevalence of Chagas disease could be used to evaluate
the cost-effectiveness of screening programmes and also could help policy makers to de-
sign health interventions concerning Chagas disease.
Introduction
One of the most remarkable changes in the epidemiology of parasitic diseases in recent decades
has been the emergence of Chagas disease in European countries and its associated transmis-
sion risk outside of endemic areas. Europe is currently hosting large populations of migrants
that were estimated to account for the 8.7% of the total European population in 2010[1]. Mi-
gration from Latin American (LA) countries steadily increased in the last two decades, especial-
ly in southern European countries such as Spain and Italy[2,3] and more recently in further
northern European countries[4].
These population movements have driven the emergence of Chagas disease in European
countries[2,3] since a considerable percentage of LA migrants are chronically infected with
Trypanosoma cruzi (T.cruzi). Consequently, the number of reported cases of Chagas disease
with and without cardiac involvement has dramatically increased in recent years especially in
those European countries such as Spain, Italy and Switzerland where most LA migrants are
hosted[5–7]. Though vector-borne transmission cannot occur in Europe (because the vector is
not present), Chagas disease can be transmitted in non-endemic countries through vertical
transmission, blood transfusion and organ transplantation. Measures to control transmission
have been designed and implemented in some countries in order to mitigate the risk of propa-
gating the disease within European borders[8–10], although these measures have been shown
to be insufficient.
The clinical importance of Chagas disease arises from the 30–40% of infected patients that
will develop cardiac and gastrointestinal involvement many years after infection[11]. Though a
significant proportion remain asymptomatic (in the so-called “indeterminate” stage of the in-
fection), they may be capable of transmitting the infection to others. Although digestive tract
disorders can be a severe health problem in chronically infected individuals, arrhythmias and
severe cardiomyopathy constitute the hallmark of the chronic phase and the most common
cause of death in people who die from Chagas disease[11]. There is no vaccine available to pre-
vent T.cruzi infection or Chagas disease. Antiparasitic therapy has proven efficacy in clearing
T.cruzi infection in acute, congenital and early chronic disease[12–16], and although there is a
Prevalence of Chagas Disease in Europe
PLOS Neglected Tropical Diseases | DOI:10.1371/journal.pntd.0003540 February 13, 2015 2 / 15
and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
trend to offer antiparasitic therapy to chronically infected adults[17], the efficacy of this mod-
erately toxic and poorly tolerated treatment in this stage of the disease remains to be
fully evaluated.
Assessing the true burden and public health implications of Chagas disease in European
countries is crucial for the design and planning of public health interventions to improve the
health of migrants in Europe and to control transmission. A study in 2009 based on aggregated
data collected from the literature and official sources estimated the total number of people in-
fected with T.cruzi in European countries as between 68,000 and 122,000 cases, with the great-
est numbers believed to be living in Spain, Italy and the United Kingdom[3]. However, the
study noted that only 4,290 cases had been reported, meaning that 95% of cases remained undi-
agnosed[3]. The fact that most chronically infected patients remain asymptomatic for long
time[11], that health professionals in non-endemic areas are generally unaware of this disease,
and that barriers to access healthcare for migrant populations are still present[1], greatly ex-
plains the high rate of underdiagnosis in European health care systems[18].
Available estimates of the burden of Chagas disease in Europe are derived by applying na-
tional population prevalence rates from countries of origin to the estimated size of the corre-
sponding migrant population[2,3]. Because country of origin prevalence is geographically
heterogeneous and because migrant populations may not be representative of the whole popu-
lation of origin (geographically or socioeconomically)[19], we hypothesized that the prevalence
of Chagas disease in LA migrants living in Europe differs from that reported in LA countries.
The main objective of this study was to establish prevalence estimates of Chagas disease in LA
migrants living in European countries. We systematically reviewed all T.cruzi prevalence studies
undertaken in (i) EU/EEA countries, (ii) in the adult population and (iii) non-hospital based and
we performed a meta-analysis to estimate the global prevalence of Chagas disease in Europe.
Methods
Search string and selection criteria
A systematic review was undertaken in accordance with the MOOSE guidelines as outlined by
the Meta-analysis of Observational Studies in Epidemiology group[20] in order to identify all
relevant publications reporting prevalence of Chagas disease in European countries belonging
to the European Union (EU) before 2004. Countries included were Spain, Portugal, France,
Italy, Germany, Belgium, Netherlands, United Kingdom, Denmark, Austria, Greece, Ireland,
Sweden and Finland. Switzerland was also included for the purpose of this study due to the
high number of Latin American migrants as well as the increasing number of confirmed cases
of T. cruzi infection in that country6. Countries joining the EU after 2004 were not included be-
cause of the extremely low number of Latin American migrants and scarce or non-existent
data about Chagas disease in these countries.
The search strategy was used to interrogate the database sources MEDLINE and Global
Health. Other sources of information used included conference proceedings, meeting abstracts,
Masters and Doctoral Theses, personal correspondence with authors of recently published ab-
stracts and manuscripts in press.
In the search string, the results were limited to all articles published up to December 2013.
The following search terms were used (Chagas OR Trypanosom) AND (Europe OR Spain OR
France OR United Kingdom OR Germany OR Belgium OR Switzerland OR Portugal OR Italy
OR Netherlands OR Sweden OR Finland OR Denmark OR Greece OR Austria OR Ireland).
The last update search was performed in January 2014.
No restrictions were placed on study date, study design or language of publication. Prevalence
studies based on community, antenatal care, blood banks or primary health care were included
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since participants’ health seeking was not likely to be specifically motivated towards Chagas dis-
ease diagnosis, whereas hospital-based studies were not included because of the high risk of selec-
tion bias. Moreover, studies assessing the prevalence of Chagas disease using different criteria to
those considered byWHO (to confirm the diagnosis, two conventional tests should be used. If
the results are not in agreement, a third test should be performed, either conventional or non-
conventional[21]) were not considered for inclusion in the meta-analysis. Prevalence studies that
had not itemized the nationalities of screened people were also not included in our study.
Data extraction
Two members of the study team assessed all selected documents for data extraction. Publica-
tions reporting survey data at the same location and period were carefully examined to avoid
duplicate information.
Prevalence data from reference sources was extracted in accordance with a standard proto-
col. Data on geographical location, year of publication and duration of the study, age popula-
tion, type of study, sampling methodology, methods of diagnosis of T.cruzi infection and
prevalence of T.cruzi infection stratified by country of origin was included. In the case of
blood-bank studies, prevalence data of T.cruzi on travelers was excluded. When country of ori-
gin data of all screened people were not completely detailed in the article, further clarifications
from the authors of these studies were requested and in case this information was not available,
these prevalence data were labeled as “other countries” only for the analysis of the pooled
prevalence data.
Disagreement was resolved by consensus between the two reviewers or through consultation
with the corresponding author of the selected papers, when necessary. Study quality was as-
sessed considering MOOSE guidelines.
Statistical methods
Pooled prevalence estimates with corresponding 95% confidence intervals (CI) were calculated
using the Freeman-Tukey double arcsine transformation. Random effects model based on the
DerSimonian & Laird method was considered. Between studies heterogeneity was assessed
using the Cochran’s Q statistic. The I2 index was also reported, indicating the variation between
studies attributed to heterogeneity rather than chance. Stratified analysis by type of study was
conducted with data from countries that showed high heterogeneity index. In case of no statis-
tically significant heterogeneity, the pooled prevalence was estimated using the fixed effect
model based on the inverse variance. The nature of the data of this review was the point preva-
lence estimates without any intervention, thus the publication bias was expected to be negligi-
ble. With the forest plot we displayed the point prevalence and 95% CI of individual studies as
well as the pooled estimates and 95% CI for all strata. All tests were two-tailed. The analyses
were performed using Stata 13 (StataCorp. 2013. Stata: Release 13. Statistical Software. College
Station, TX: StataCorp LP) and StatsDirect 2.8.0 (StatsDirect,Altrincham, Cheshire, UK).
All funding sources had no role in study design, data collection, analysis, interpretation, or
writing of the report. All authors had full access to the study data and had final responsibility
for the decision to submit for publication.
Results
Study selection
A list of all the articles retrieved from the literature search is available in the S1 Text. After re-
moval of duplicates 1296 potentially eligible articles were identified by title-search. 1070
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irrelevant articles were eliminated by title-search because they were not related to Chagas dis-
ease or to the epidemiology of the disease and 226 potentially relevant articles were accepted
for review of the abstract. Of these, 126 did not contain prevalence data leaving a total of 100
papers (including 16 papers which did not contain any abstract) plus one study which was in-
troduced after reviewing the references of other article) that were retrieved for full-text screen-
ing. Out of them, 52 were rejected since they did not provide any data of prevalence, 7 papers
were further rejected since they were hospital-based studies, 16 papers were ruled out since the
information about country of origin of all screened people was not provided; 5 articles were ex-
cluded because the study had not been conducted in Europe, 1 article because the data-base
had been already included in a another study, 2 articles because the inclusion criteria did not
full-fit the WHO criteria for the diagnosis of Chagas disease. Finally, data from 18 papers were
finally included in the meta-analysis (Fig. 1).
Three studies were undertaken in blood banks,[22–24] eight in antenatal units,[8,25–31] six
in primary care settings or communities[6,32–36] and one study provided data both from
blood bank and antenatal settings.[37] Data from 10,884 individuals was analyzed. Data were
Fig 1. Flow diagram for study selection.
doi:10.1371/journal.pntd.0003540.g001
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only available from studies conducted in five European countries: Spain (n = 8,148), France
(n = 972), Switzerland (n = 1,317), Italy (n = 347) and Germany (n = 100). A summary of the
included studies is provided in Table 1.
Country of origin data by study type
Estimates of pooled Chagas disease prevalence in publications ranged from 0 to 15.9%. The
random effect pooled prevalence was 4.2% (95% CI: 2.2–6.7%); and the heterogeneity of Cha-
gas disease prevalence among studies included in the meta-analysis (with widely varied popula-
tion groups originating from 14 different countries) was very high (I2 = 97%, p<0.001).
Prevalence estimates from studies conducted in blood bank studies (0.5%, 95%: 0.3–0.9%) were
considerably lower than those derived from primary health care or community level (8.7%,
95%CI: 7.7–9.9%) and antenatal screening (6.5%, 95% CI: 5.8–7.1%) settings (p<0.001,
Table 2). These differences were highest in data from Argentina (I2 72.4%) and Bolivia
(I2 87.4%). Stratified analysis by type of study was conducted with data from these two coun-
tries showing high heterogeneity within PHC/community and antenatal studies. Studies con-
ducted in blood banks showed more homogeneous prevalence estimates (Table 3).
Pooled migrant data by country of origin (regardless of setting)
Chagas disease prevalence estimates varied substantially by country of origin (Table 3). Mi-
grants to Europe from Bolivia had the highest prevalence of Chagas disease (18.1%, 95% CI:
13.9–22.7), followed by those from Paraguay (5.5%, 95% CI: 3.5–7.9). Individuals born in Cen-
tral American countries that showed high prevalence of Chagas disease were from El Salvador
(5.6%, 95% CI: 1.6–11.7), Honduras (3.7%, 95% CI: 1.3–7.4) and Nicaragua (4.57%, 95% CI:
0.8–11.3), although the number of screened subjects was very low (67, 136, 50 respectively)
(Table 4). Prevalence amongst Argentinian migrants was 2.2% (95% CI: 0.8–4.1) and the preva-
lence amongst migrants from other countries in all studied groups was under 1% (Table 4). No
cases of Chagas disease were detected in migrants to Europe from Uruguay, Venezuela, Pana-
ma, Guatemala or Mexico. Fig. 2 shows the results from random effects model pooled T. cruzi
prevalence and heterogeneity by country of birth.
Comparison of migrant data to country of origin data
When compared to PAHO estimates of national prevalence rates the pooled prevalence of Cha-
gas disease in migrants from Bolivia and from Paraguay living in Europe were significantly
higher (prevalence ratio 2.67 and 2.17 respectively). The prevalence observed in Central Ameri-
can countries was also higher than the official in-country estimates, albeit with large confidence
intervals due to small sample sizes. Table 4 shows prevalence estimates from the meta-analysis
compared to the available estimates from LA countries.
Discussion
The true burden and public health implications of imported Chagas disease in European coun-
tries are still unclear, hampering the possibility of designing and implementing targeted public
health interventions to improve the health of infected individuals and control the transmission
in European countries. One of the main limitations to obtain accurate estimates is the uncer-
tain prevalence of Chagas disease in the migrant populations in Europe, that likely differs from
the estimates from LA countries and that is closely linked to the country and region of origin
[19]. Data presented here indicate that overall 4.2% of LA individuals living in European coun-
tries are chronically infected with Chagas disease which suggests that European countries
Prevalence of Chagas Disease in Europe
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Table 1. Main characteristics of the studies included in the meta-analysis.
Author Country Study
Year
Study type Sampling
characteristics
Age Diagnostic method Prevalence
(%)
n Reference
Angheben Italy 2008-? /
2008–
2009
Blood bank/
Antenatal
care
Prospective general
screening. No active
community outreach
Adult Immunochromatographic assay
(Chagas Quick Test, Cypress
Diagnostics, Belgium); BioELISA
Chagas, Biokit S.A., Spain; DRG
CHAGAS IgG, Germany
0 245 [37]
Avila-
Arzanegui
Spain Dec
2008—
Jan
2010
Antenatal
care
Prospective general
screening. No active
community outreach
Adult Indirect immunoﬂuorescence
(MarDx, Inc. Trinity Biotech plc
Bray, Co. Wicklow, Ireland); ELISA
T. cruzi Ab, Dia. Pro, Milán, Italy);
ORTHO T. cruzi ELISA Test
System, Buckinghamshire, UK.
12 158 [25]
Barona-
Vilar
Spain 2009–
2010
Antenatal
care
Multicentre retrospective
cross-sectional survey of
microbiological records
Adult Ortho1 T. cruzi ELISA, Test
System, (Johnson & Johnson,
USA); Chagatek ELISA,
(bioMerieux, France) and T. cruzi
Ab, DIAPRO, (Diagnostic
BioProbes, Italy); Agglutination
assay, IDPaGIA Chagas, DiaMed
AG, Switzerland;
Immunochromatographic assay;
Stick Chagas, Operon SA, Spain
11.6 1945 [26]
El Ghouzzi France April
2007-
Oct
2008
Blood bank Prospective general
screening. No active
community outreach
Adult ELISA cruzi, manufactured by
bioMérieux Brazil S.A (Estrada do
Mapuã, Jacarepaguã, RJ, Brazil);
Bioelisa CHAGAS (Biokit, Lliçà
d’Amunt, Spain)
0.3 972 [22]
Frank Germany May—
August
1995
Community
study
Religious support group
of Latin Americans
recruited at their
meetings. Informed
consent sought.
Adult Indirect immunoﬂuorescence test
(IIF) using ﬁxed epimastigotes
(Bits/Germany) as antigen; In
house ELISA for T. cruzi
antibodies
2 100 [32]
Gabrielli Italy 2010–
2012
Blood bank Prospective general
screening. No active
community outreach
Adult Immunochromatographic assay
(ICT) (Chagas Quick Test,
Cypress Diagnostics, Langdorp,
Belgium; BioELISA Chagas, Biokit
S.A., Barcelona, Spain; NovaLisa
Chagas ELISA test, Nova Tec
Immunodiagnostica, GmbH,
Dietzenbach, Germany
0.98 102 [23]
Jackson Switzerland Jun- Dec
2008
Primary
health care
and
community
study
Prospective recruitment in
primary care unit.
Community outreach:
active case ﬁnding in
cultural centres, churches
and migrant associations.
Recruitment sessions in
churches attended by
migrants.
>16
y
ELISA cruzi, Biomérieux, Brazil
and Bioelisa Chagas, Biokit,
Spain),
12.85 1012 [6]
Orti-Lucas Spain Feb
2005—
Jul 2007
Antenatal
care
Prospective general
screening. No active
community outreach
Adult Immunoprecipitación particle gel
immuno assay—Diamed (IP)
(reference BO20011–01.04);
Indirect immunoﬂuorescence,
Immunoﬂour Chagas—Inverness
Medical (reference 20–03648;
ELISA Dade Behering (reference
CHAG0560DB)
9.69 382 [27]
(Continued)
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Table 1. (Continued)
Author Country Study
Year
Study type Sampling
characteristics
Age Diagnostic method Prevalence
(%)
n Reference
Martinez
de Tejada
Switzerland 2008 Antenatal
care
Prospective general
screening. No active
community outreach
Adult Immunoﬂuorescence in house 1.97 305 [28]
Muñoz-
Vilches
Spain April
2007—
April
2011
Antenatal
care
Prospective general
screening. No active
community outreach
Adult ELISA-in house (ELISA-CNM
Centro Nacional de Microbiología-
); Indirect immunoﬂuorescence
assay, IFI-in house (IFI-CNM)
1.53 261 [29]
Muñoz Spain March
2005—
Sept
2007
Antenatal
care
Prospective general
screening. No active
community outreach
Adult BioELISA Chagas; Biokit S.A,
Spain; In house ELISA (crude
antigen from T. cruzi
epimastigotes)
3.41 1350 [8]
Navarro Spain May
2008—
Dec
2009
Community
study
Non-governmental
organisations and
migrants’ associations
promoted talks on the
disease to migrants in
different community
settings.
Adult Rapid immunochromatographic
test (Simple Chagas WB, Operon);
Filter paper sent to the National
Microbiology Centre for
conﬁrmation: using Indirect
ﬂuorescent antibody technique and
ELISA assay.
15.94 276 [33]
Patricio
Talayero
Spain 2005–
2007
Antenatal
care
Prospective general
screening No active
community outreach
Adult Immunoprecipitation, ID-PaGIA
Chagas Antibody Test, (reference
B020011–01.04 de Diamed-Id);
Indirect immunoﬂuorescence
(Innogenetics, ref. 20–03648)
4.65 624 [30]
Piron Spain Sept
2005—
Sept
2006
Blood bank Prospective general
screening. No active
community outreach
Adult Particle gel immunoassay (ID-
PaGIA, DiaMed, Cressier
surMorat, Switzerland); Chagas
bioelisa assay (Biokit, Lliçá
d’Amunt, Spain)
0.66 1770 [24]
Ramosa Spain 2006–
2010
Antenatal Prospective general
screening. No active
community outreach
Adult Particle gel immunoassay (ID-
PaGIA, DiaMed, Cressier
surMorat, Switzerland); Chagas
bioelisa assay (Biokit, Lliçá
d’Amunt, Spain)
1.28 545 [31]
Ramosb Spain Nov
2009—
Nov
2010
Community
study
Informal links with
migrants’ and migrants’
associations through
social and cultural
activities to deliver
information and conduct
recruitment
Adult In-house ELISA (antigen prepared
from epimastigotes obtained from
a culture of the stationary phase of
two strains of T. cruzi, (MC and T)
and from another T. cruzi I (Dm28);
In-house Indirect
immunoﬂuorescent antibody test
(antigens prepared from cultures of
epimastigotes in the stationary
phase of the same strains of T.
cruzi used in ELISA).
6.47 201 [34]
Roca Spain Oct
2007—
Oct
2009
Primary
Health care
Prospective general
screening. No active
community outreach
Adult Immunochromatographic test (ICT)
that uses recombinant antigens of
T. cruzi (TcD, TcE, PEP-2 and
SAPA); In-house ELISA with whole
T. cruzi epimastigote antigens;
Commercial ELISA (recombinant
antigens TcD, TcE, PEP-2 and
TcLo1.2.)
2.87 766 [35]
Soriano Spain March
2006—
March
2007
Primary
Health Care
Prospective general
screening. No active
community outreach
15–
45 y
Chagas bioelisa assay (Biokit,
Lliçá d’Amunt, Spain); In-house
ELISA (epimastigote antigens
obtained by sonication from the
epimastigote forms of the Maracay
strains of T. cruzi)
4.31 116 [36]
doi:10.1371/journal.pntd.0003540.t001
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hosting LA migrant population should seriously evaluate the need to address the detection,
management and control of Chagas disease. However, concealed within the overall point esti-
mate of 4.2% is marked heterogeneity both between and within migrants from different LA
countries. The data presented here are a useful starting point for understanding the burden of
Chagas disease in migrants to Europe whilst also highlighting the profound knowledge gap and
clear need for more systematic, larger scale investigation.
Table 2. Heterogeneity of pooled prevalence estimates of Chagas disease by type of study recruitment setting.
Positive Screened Prevalence (%) 95% CI. % weight (random)
PHC 216 2471 8.7 7.7–9.9 33.27
blood donors 14 2629 0.5 0.3–0.9 33.29
pregnancy 374 5784 6.5 5.8–7.1 33.43
Random Effects Pooled Prevalence 604 10884 4.2 0.7–10.8 100.00
TEST FOR HETEROGENEITY
Q Heterogeneity chi-squared = 319.05 (d.f. = 2) p = 00000
I2 (variation in Prevalence attributable to heterogeneity) = 99.4%
Moment-based estimate of between-study variance Tau2 = 0.0479
doi:10.1371/journal.pntd.0003540.t002
Table 3. Country-speciﬁc prevalence of Chagas disease by type of study and values of results of heterogeneity tests among different type of
studies.
Prevalence PHC*/
Community studies (95% CI)
Prevalence Blood bank
studies (95% CI)
Prevalence Antenatal
studies (95% CI)
HeterogeneityI2 p-value (Q Heterogeneity
chi-squared)
Argentina 2.6 (0.3–9.2) 1 0.5 (0.1–1.9) 2 2.8(1.5–4.9) 3 72.4 0.03
Bolivia 21.6 (19–24.4)4 10.7 (4.7–19. 9)5 26.5 (24–29)6 87.4 <0.001
Brazil 0.4 (0–2) 0 (0–1.1) 0.9 (0.2–2.6) 46.4 0.2
Chile 0 (0–0.1) 0 (0–2.1) 1.3 (0–6.8) 5.3 0.3
Colombia 0 (0–1.9) 0 (0–0.7) 0.7 (0.2–1.4) 65.5 0.06
Ecuador 0 (0–1.3) 0.4 (0–2.2) 0.4 (01–0.8) 0 0.5
El
Salvador
0 (0–30.8) 9.1 (1.1–29.2) 0 (0–0.1) 43.8 02
Honduras 0 (0–9.7) 0 (0–21.8) 3.5 (0.7–10) .0 0.4
Mexico 0 0 0 - -
Nicaragua 0 (0–14.2) 0 (0–28.5) 6.7 (0.2–31.9) 0 0.4
Paraguay 3.9 (1.6–7.8) 4.5 (0.1–22.8) 6 (3.1–10.6) 0 0.7
Peru 0.3 (0–1.9) 0 (0–1.6) 0.6 (0.1–1.7) 0 0.4
Uruguay 0 0 0 - -
Venezuela 0 0 0 - -
95% CI—95% conﬁdence interval; All country test for heterogeneity: Q Heterogeneity chi-squared = 319.1 (d.f. = 2), p< 0. 001, I2 (variation in Prevalence
attributable to heterogeneity) = 99.4%, Moment-based estimate of between-study variance Tau2 = 0.05;
1: I2 index of heterogeneity 79.5%;
2: I2 index of heterogeneity 0%;
3: I2 index of heterogeneity 51.5%;
4: I2 index of heterogeneity 79.4%;
5: I2 index of heterogeneity 0%;
6: I2 index of heterogeneity 85.1%
doi:10.1371/journal.pntd.0003540.t003
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The high degree of prevalence heterogeneity found among different countries of origin was
expected. Bolivian migrants had the highest prevalence of Chagas disease with 18% of the mi-
grant population infected with T.cruzi. This is concordant with data from high endemic areas
in Bolivia from 2004 to 2009, in which 23.3% of pregnant women were estimated to be infected
with T.cruzi[38]. However, in comparison to PAHO estimates[39] of the prevalence of T.cruzi
infection in the whole Bolivian population (6.75%), prevalence of the infection in migrants is
2.67 fold higher. Thus, extrapolating PAHO data to estimate the prevalence of Chagas disease
in a particular European country would significantly underestimate the real burden of Chagas
disease in Bolivian migrant populations. One possible explanation for this difference is the fact
that an over-representative proportion of Bolivian migrants are coming from hyperendemic
areas of Chagas disease in Bolivia such as the departments of Tarija, Cochabamba or Chuqui-
saca and the proportion of migrants coming from low endemic areas in Bolivia such as La Paz
is lower. High variation in T. cruzi prevalence has also been described with pregnant women
living in high risk areas such as Chuquisaca (37% infected) or Tarija (38%) being more than
seven times more likely to be infected as compared with those living in low-endemic regions
such as La Paz (5%)[38].
Similarly, migrants from Paraguay also presented higher prevalence of Chagas disease as
compared to overall in-country estimates[39], but comparable with studies undertaken in hy-
perendemic areas (12.7%)[40]. This may reflect a higher proportion of people from Paraguay
migrating from highly endemic areas to Europe as suggested for Bolivian migrants, or simply
that migrants from high endemic areas are more likely to be screened than those coming from
big cities. Our data show opposite results in migrants from Argentina, with lower prevalence
(2.2%) as compared to the overall prevalence estimated in Argentina (4.13%). Again, this may
Table 4. Pooled T. cruzi prevalence by country of origin in Latin American migrants from European countries.
Country Number
screened
Number of
seropositives
Country-speciﬁc
prevalence* (%)
95% CI Prevalence in country of origin
(National level) PAHO (%)[39]
Prevalence
ratio
Argentina 875 16 2.2 0.80–413 4.13 0.53
Bolivia 2264 541 18 13.9–
22.66
6.75 2.67
Brazil 954 4 0.6 0.16–1.12 1.02 0.59
Chile 290 1 1 0.17–2.36 0.99 1.01
Colombia 1627 6 0.5 0.15–0.92 0.96 0.52
Ecuador 2131 7 0.4 0.18–0.72 1.74 0.23
El
Salvador
67 2 3.7 1.62–11.7 3.37 1.10
Honduras 136 3 4.2 1.27–7.36 3.05 1.38
Mexico 166 0 1.5^ 0.24–3.76 1.03 1.46
Nicaragua 50 1 4.6 0.76–11.3 1.14 4.04
Paraguay 385 19 5.5 3.46–7.91 2.54 2.17
Peru 1029 4 0.6 0.23–1.18 0.69 0.87
Uruguay 248 0 0.8^ 0.08–2.24 0.66 1.21
Venezuela 311 0 0.9^ 0.16–2.22 1.16 0.78
CI: Conﬁdence Interval; PAHO: Pan American Health Organization;
*Weighted prevalence with Random effect model;
^ although there was not any reported case of Chagas disease in migrants coming from this country, the weighted prevalence is not “0” due to the
Random Effect model
doi:10.1371/journal.pntd.0003540.t004
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be attributable to the demography of migrant populations, in this case perhaps predominantly
migration from urban parts of this country.
Prevalence amongst migrants from other countries including Brazil, Peru, Colombia and
Venezuela was around or lower than 1%. A somewhat surprisingly high pooled prevalence of
Chagas disease was found in migrants coming from El Salvador, Honduras and Nicaragua,
even though more data is needed to achieve accurate prevalence estimates for these popula-
tions, as sample size were not large. However, it is noteworthy that these data differ significant-
ly from PAHO estimates, in the case of Nicaragua representing a four-fold increase. Although
data on the prevalence of Chagas disease in Central America is scarce, a prevalence as high as
8,5% was found in a sample taken from patients in the area of Somoto in Nicaragua[41]. The
heterogeneity and smaller size of migrant communities analysed in some studies, especially in
the case of countries from Central America, with relatively little representation in European
countries, represents a challenge to achieve statistically relevant information. On the other
hand, our results may also question the validity of PAHO estimates, highlighting the need for
updated prevalence data in LA countries.
Available data estimating the prevalence of Chagas disease in European countries are heavi-
ly reliant on research studies conducted in tertiary referral centres that tend to overestimate the
true population prevalence[19]. This systematic review excluded hospital-based studies and
Fig 2. Forest plots of prevalence of Chagas disease by country of origin of Latin Americanmigrants.
doi:10.1371/journal.pntd.0003540.g002
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studies conducted in reference units because of the risk of overestimating the prevalence due to
selection bias. Studies conducted in antenatal care, blood banks, primary health care or com-
munity-based were included in the analysis. Even though the profile of participants differs
from one type of study to another, we were not expecting large selection bias since in most
cases the reason for attending the health setting was not to seek a diagnosis of Chagas disease.
However, we found a high heterogeneity of prevalence by study type, showing higher estimates
in studies conducted in the community and primary care and in antenatal care compared to
those conducted in blood banks. This heterogeneity was mainly found in data from Bolivia and
Argentina. Although it is possible that these differences are caused by the different recruitment
settings, these studies could have overestimated the prevalence due to selection bias. Random
selection methods were not used to recruit participants in any of the studies found in the litera-
ture search[6,32–34]. Unbiased community based prevalence data are needed to understand
the true prevalence of disease. Moreover, self-exclusion from transfusion services due to pre-
screening ineligibility could also be the reason for lower prevalence in blood-bank studies. Fi-
nally, migrants going to blood-banks maybe older, with longer stays in Europe and from differ-
ent socio-economical background compared to migrants attending PHC centers or
maternities, which could also explain in part the lower prevalence in blood-banks compared
with the other settings.
Another limitation of this study is the fact that pooled estimates do not capture the hetero-
geneity that exists within some regions in LA countries. Thus, there is a need for additional
sub-national-level data to make decisions about the implementation of screening and
management programmes.
Updated data from LA migrants in Europe is needed taking into account (i) changes in mi-
gration flows, particularly in the context of the current economic crisis; (ii) undocumented mi-
grants and (iii) LA migrants with European citizenship. Health information systems in most
European countries currently lack capacity to analyze data based on migration status and/or
country of origin. The unclear definition of who constitutes a migrant, and the use of different
variables as a proxy for migration status (nationality, ethnicity, origin), including the lack of
data about country of birth in many countries hampers the possibility to gather and compare
data between countries[1].This is especially relevant in the case of Chagas disease, where large
differences in prevalence are observed between different LA countries and even within different
regions of the same country[5,11].
Providing policy makers in European countries with accurate data about country-specific
prevalence of Chagas disease could help them in the design of health interventions concerning
Chagas disease. Furthermore these differences acquire importance when the cost-effectiveness
of screening programmes is assessed since variations in prevalence could alter the results of the
economic analysis and provide policy makers with incorrect information.
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